TELL enables patients and clinicians to make timely decisions about brain health through automated speech analysis, a cutting-edge, non-invasive method to identify, discriminate, and monitor neurodegenerative diseases.
These disorders, including Alzheimer’s and Parkinson’s disease, affect 100 million people worldwide and cost over one trillion dollars annually in Latin America alone, creating an urgent need for inexpensive, flexible, and consistent markers that favor early detection.
Current diagnostic tools are slow, expensive, subjective, and often inaccessible to those in non-urban areas. This leads to expensive R&D, delayed treatments, and underserved patients. TELL offers a solution with automated, affordable, and scalable speech and language tests that use artificial intelligence to capture reliable markers of brain anomalies.
Latest news & updates
DESAISIV, a cutting-edge InsurTech startup, raises $2 million in a pre-seed funding from 500 Global, Terra VC and various family offices.View more
Fintech startup Daleel’s game-changing partnership with National Bank of Bahrain (NBB) propels fintech solutions to new heights.View more
VAs are highly skilled professionals who provide remote admin, technical, and creative assistance to businesses and individuals.View more
From Darkness to Hope: Zilia Illuminates the Path to Early Detection of Preventable Blindness. Zilia Ocular. A Glimpse into the Future.View more